Premium
Local drug delivery of 0.5% azithromycin in the treatment of chronic periodontitis among smokers
Author(s) -
Pradeep AR,
Bajaj P,
Agarwal E,
Rao NS,
Naik SB,
Kalra N,
Priyanaka N
Publication year - 2013
Publication title -
australian dental journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.701
H-Index - 71
eISSN - 1834-7819
pISSN - 0045-0421
DOI - 10.1111/adj.12019
Subject(s) - medicine , azithromycin , chronic periodontitis , scaling and root planing , placebo , periodontitis , randomized controlled trial , clinical trial , antibiotics , dentistry , placebo group , adjunctive treatment , pathology , alternative medicine , microbiology and biotechnology , biology
Background Along with conventional periodontal surgical therapy, local delivery of antibiotics may provide more effective treatment in smokers by targeting tissue‐invasive bacteria. The aim of this randomized, placebo‐controlled, double‐masked clinical trial was to evaluate the adjunctive effects of subgingivally delivered 0.5% azithromycin ( AZM ) as an adjunct to scaling and root planing ( SRP ) in the treatment of chronic periodontitis in smokers. Methods Fifty‐four patients were randomized and categorized into two treatment groups: Group 1 – 26 subjects who received (SRP) plus placebo gel and Group 2 – 28 subjects who received (SRP) plus 0.5% azithromycin. Clinical parameters were recorded at baseline, 3, 6 and 9 months. They included Plaque Index (PI), modified Sulcus Bleeding Index ( mSBI ), probing depth (PD) and clinical attachment level (CAL). Results Azithromycin resulted in significant improvements. A single application of AZM resulted in attachment gain at 9 months of 2.44 ± 0.64 mm as compared to 0.18 ± 0.68 mm for the placebo. Similarly, pocket depth and PI were significantly reduced but no change in the mSBI was noted. Conclusions When compared to the placebo, the adjunctive use of 0.5% AZM resulted in significant improvement in clinical outcome in the treatment of chronic periodontitis among smokers.